Intervacc is trading 3.2% down at €0.09, extending a week of small, steady declines despite a lack of fresh company news.
- The downward move appears to reflect ongoing weakness in the high-volatility, unprofitable biotech name rather than a specific catalyst.
- There have been no new filings, earnings reports, or major announcements reported by mainstream financial news sources to account for the price action.